Cahaba Wealth Management Inc. Has $242,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Cahaba Wealth Management Inc. reduced its position in Zoetis Inc. (NYSE:ZTSFree Report) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,228 shares of the company’s stock after selling 140 shares during the period. Cahaba Wealth Management Inc.’s holdings in Zoetis were worth $242,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Evermay Wealth Management LLC raised its position in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new position in shares of Zoetis during the 1st quarter valued at $26,000. VisionPoint Advisory Group LLC acquired a new stake in shares of Zoetis in the 2nd quarter valued at $29,000. Finally, Moisand Fitzgerald Tamayo LLC boosted its holdings in Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Zoetis stock traded down $2.01 during mid-day trading on Tuesday, reaching $165.01. The company had a trading volume of 2,376,954 shares, compared to its average volume of 2,720,826. The company has a 50 day moving average of $184.62 and a 200-day moving average of $181.88. Zoetis Inc. has a 52 week low of $151.03 and a 52 week high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market cap of $75.47 billion, a price-to-earnings ratio of 32.55, a PEG ratio of 2.58 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business earned $1.15 earnings per share. On average, sell-side analysts expect that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.05%. Zoetis’s dividend payout ratio is currently 34.12%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. BNP Paribas initiated coverage on Zoetis in a research report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 price target for the company. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price target on shares of Zoetis in a report on Tuesday, December 19th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $222.11.

Read Our Latest Stock Analysis on Zoetis

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $408,453 in the last 90 days. 0.15% of the stock is currently owned by company insiders.

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.